Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| See historical APLS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 10 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Dec 10 | Calm After Storm | Range Contraction | 0.00% |
| Dec 10 | Wide Bands | Range Expansion | 0.00% |
| Dec 7 | Calm After Storm | Range Contraction | 1.41% |
| Dec 7 | Upper Bollinger Band Walk | Strength | 1.41% |
| Dec 7 | Wide Bands | Range Expansion | 1.41% |
| Dec 6 | Calm After Storm | Range Contraction | -0.06% |
| Dec 6 | Upper Bollinger Band Walk | Strength | -0.06% |
| Dec 6 | Inside Day | Range Contraction | -0.06% |
| Dec 6 | Wide Bands | Range Expansion | -0.06% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-06
- Sector: Healthcare
- Industry: Biopharmaceuticals
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more APLS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 32.0 |
| 52 Week Low | 11.45 |
| Average Volume | 294,756 |
| 200-Day Moving Average | 19.6449 |
| 50-Day Moving Average | 15.3821 |
| 20-Day Moving Average | 15.811 |
| 10-Day Moving Average | 16.765 |
| Average True Range | 1.4005 |
| ADX | 20.1 |
| +DI | 31.1639 |
| -DI | 16.2239 |
| Chandelier Exit (Long, 3 ATRs ) | 16.3335 |
| Chandelier Exit (Short, 3 ATRs ) | 17.4415 |
| Upper Bollinger Band | 18.5991 |
| Lower Bollinger Band | 13.0229 |
| Percent B (%b) | 0.89 |
| BandWidth | 35.267851 |
| MACD Line | 0.7281 |
| MACD Signal Line | 0.4009 |
| MACD Histogram | 0.3272 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.59 | ||||
| Resistance 3 (R3) | 19.41 | 18.71 | 19.32 | ||
| Resistance 2 (R2) | 18.71 | 18.30 | 18.79 | 19.23 | |
| Resistance 1 (R1) | 18.34 | 18.05 | 18.53 | 18.52 | 19.14 |
| Pivot Point | 17.64 | 17.64 | 17.73 | 17.72 | 17.64 |
| Support 1 (S1) | 17.27 | 17.23 | 17.46 | 17.45 | 16.82 |
| Support 2 (S2) | 16.57 | 16.98 | 16.65 | 16.73 | |
| Support 3 (S3) | 16.20 | 16.57 | 16.64 | ||
| Support 4 (S4) | 16.38 |
